A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients.

Trial Profile

A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Planned End Date changed from 1 Nov 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov .
    • 21 May 2012 Planned end date changed from 1 Feb 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top